SMAD3 and Hepatic fibrosis: For instance, miR-34a-5p could inhibit liver fibrosis development by affecting TGF-β/Smad3 pathway in HSCs (Feili et al., 2018); miR-98 inhibits HSC activation, consequently attenuating the development of liver fibrosis (Wang Q. et al., 2020); miR-29a and miR-652 prevent liver fibrosis by suppressing CD4+ T cell differentiation (Xuan et al., 2017); TGF-β can induce liver fibrosis by downregulation of augmenter of liver regeneration in HSCs that is mediated by miR-181a (Gupta et al., 2019).